FIGURE 5.

Distinct effects of HDAC6 and Class IIa HDACs inhibition on LPS-induced cytoskeletal signaling. (a) HLMVEC were pretreated either with Class IIa HDAC inhibitor (TMP269, 100 nM), HDAC6 inhibitor (Tubastatin A, 5 μM), or vehicle (control, 0.1% dimethyl sulfoxide) for 2 h then challenged with LPS (0.2 mg/ml) for 4 h. (a) Western blot image represents the changes in p-MYPT1 and pp-MLC levels, in conjunction with changes in tubulin acetylation. (b–d) Quantitative analysis of p-MYPT1, pp-MLC, and acetylated tubulin with densitometry. Data are shown as mean ± SEM (n = 4 experiments). HDACs, histone deacetylases; HLMVEC, human lung microvascular endothelial cell; LPS, lipopolysaccharide. *p < .05, **p < .01, ***p < .0001 versus control and versus LPS treatment